Combination of Rapamycin and Resveratrol for Treatment of Bladder Cancer

Journal of Cellular Physiology

Volumn 232, Issue 2, 2017, Pages 436-446

  Alayev, Anya ^a   Salamon, Rachel S ^a   Schwartz, Naomi S ^a   Berman, Adi Y ^a   Wiener, Sara L ^a   Holz, Marina K ^a,b  

^a YESHIVA UNIVERSITY   (United States)

^b ALBERT EINSTEIN CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4B; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN KINASE B; PROTEIN MCL 1; PROTEIN PDCD4; PROTEIN PRAS40; RAPAMYCIN; RESVERATROL; SURVIVIN; TUBEROUS SCLEROSIS COMPLEX PROTEIN 1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; STILBENE DERIVATIVE; TARGET OF RAPAMYCIN KINASE; TUBEROUS SCLEROSIS COMPLEX 1 PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BLADDER CANCER; CELL DEATH; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; APOPTOSIS; CELL LINE; CELL MOTION; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; FIBROBLAST; MAMMALIAN EMBRYO; METABOLISM; MOUSE; PATHOLOGY; URINARY BLADDER NEOPLASMS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; EMBRYO, MAMMALIAN; ENZYME ACTIVATION; FIBROBLASTS; HUMANS; MICE; MULTIPROTEIN COMPLEXES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIROLIMUS; STILBENES; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 84977479067     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.25443     Document Type: Article

References (51)

1. Abraham R, Pagano F, Gomella LG, Baffa R. 2007. Chromosomal deletions in bladder cancer: Shutting down pathways. Front Biosci 12:826–838.
2. Alayev A, Berger SM, Holz MK. 2015a. Resveratrol as a novel treatment for diseases with mTOR pathway hyperactivation. Ann N Y Acad Sci 1348:116–123.
3. Alayev A, Berger SM, Kramer MY, Schwartz NS, Holz MK. 2014a. The combination of rapamycin and resveratrol blocks autophagy and induces apoptosis in breast cancer cells. J Cell Biochem 116:450–457.
4. Alayev A, Holz MK. 2013. MTOR signaling for biological control and cancer. J Cell Physiol 228:1658–1664.
5. Alayev A, Salamon RS, Sun Y, Schwartz NS, Li C, Yu JJ, Holz MK. 2015b. Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors. Am J Respir Cell Mol Biol 53:637–646.
6. Alayev A, Sun Y, Snyder RB, Berger SM, Yu JJ, Holz MK. 2014b. Resveratrol prevents rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cells. Cell Cycle 13:371–382.
7. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML. 2004. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909–918.
8. Bambury RM, Rosenberg JE. 2013. Actionable mutations in muscle-invasive bladder cancer. Curr Opin Urol 23:472–478.
9. Bamias A, Tiliakos I, Karali MD, Dimopoulos MA. 2006. Systemic chemotherapy in inoperable or metastatic bladder cancer. Ann Oncol 17:553–561.
10. Bartholomeusz C, Gonzalez-Angulo AM. 2012. Targeting the PI3 K signaling pathway in cancer therapy. Expert Opin Ther Targets 16:121–130.
11. Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, Witters LA, Ellisen LW, Kaelin WG, Jr. 2004. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 18:2893–2904.
12. Burris HA, 3rd. 2013. Overcoming acquired resistance to anticancer therapy: Focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol 71:829–842.
13. Cairns P, Shaw ME, Knowles MA. 1993. Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene 8:1083–1085.
14. Cancer Genome Atlas Research Network. 2014. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507:315–322.
15. Chen M, Cassidy A, Gu J, Delclos GL, Zhen F, Yang H, Hildebrandt MA, Lin J, Ye Y, Chamberlain RM, Dinney CP, Wu X. 2009. Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis 30:2047–2052.
16. Ching CB, Hansel DE. 2010. Expanding therapeutic targets in bladder cancer: The PI3 K/Akt/mTOR pathway. Lab Invest 90:1406–1414.
17. Chiong E, Lee IL, Dadbin A, Sabichi AL, Harris L, Urbauer D, McConkey DJ, Dickstein RJ, Cheng T, Grossman HB. 2011. Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. Clin Cancer Res 17:2863–2873.
18. Courtney KD, Corcoran RB, Engelman JA. 2010. The PI3 K pathway as drug target in human cancer. J Clin Oncol 28:1075–1083.
19. Elliott AY, Bronson DL, Cervenka J, Stein N, Fraley EE. 1977. Properties of cell lines established from transitional cell cancers of the human urinary tract. Cancer Res 37:1279–1289.
20. Fajkovic H, Halpern JA, Cha EK, Bahadori A, Chromecki TF, Karakiewicz PI, Breinl E, Merseburger AS, Shariat SF. 2011. Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol 29:457–463.
21. Fechner G, Classen K, Schmidt D, Hauser S, Muller SC. 2009. Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer. Urology 73:665–668; discussion 668–669.
22. Garcia JA, Danielpour D. 2008. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 7:1347–1354.
23. Guo Y, Chekaluk Y, Zhang J, Du J, Gray NS, Wu CL, Kwiatkowski DJ. 2013. TSC1 involvement in bladder cancer: Diverse effects and therapeutic implications. J Pathol 230:17–27.
24. Hansel DE, Platt E, Orloff M, Harwalker J, Sethu S, Hicks JL, De Marzo A, Steinle RE, Hsi ED, Theodorescu D, Ching CB, Eng C. 2010. Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am J Pathol 176:3062–3072.
25. Houede N, Pourquier P. 2015. Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: Its potential use in the treatment of bladder cancers. Pharmacol Ther 145:1–18.
26. Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, Pirun M, Sander C, Socci ND, Ostrovnaya I, Viale A, Heguy A, Peng L, Chan TA, Bochner B, Bajorin DF, Berger MF, Taylor BS, Solit DB. 2012. Genome sequencing identifies a basis for everolimus sensitivity. Science 338:221.
27. Kato T, Irwin RJ, Jr., Prout GR, Jr. 1977. Cell cycles in two cell lines of human bladder carcinoma. Tohoku J Exp Med 121:157–164.
28. Kim JJ. 2012. Recent advances in treatment of advanced urothelial carcinoma. Curr Urol Rep 13:147–152.
29. Knowles MA, Platt FM, Ross RL, Hurst CD. 2009. Phosphatidylinositol 3-kinase (PI3 K) pathway activation in bladder cancer. Cancer Metastasis Rev 28:305–316.
30. Lin CC, Hsu CH, Pu YS, Vogelzang NJ. 2008. Systemic therapy for metastatic urothelial carcinoma. BJU Int 101:795–803.
31. Lindgren D, Sjodahl G, Lauss M, Staaf J, Chebil G, Lovgren K, Gudjonsson S, Liedberg F, Patschan O, Mansson W, Ferno M, Hoglund M. 2012. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS ONE 7:e38863.
32. Liu P, Cheng H, Roberts TM, Zhao JJ. 2009. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8:627–644.
33. Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. 2005. Rheb binds and regulates the mTOR kinase. Curr Biol 15:702–713.
34. Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, Brachmann S, Fritsch C, Dorsch M, Chene P, Shoemaker K, De Pover A, Menezes D, Martiny-Baron G, Fabbro D, Wilson CJ, Schlegel R, Hofmann F, Garcia-Echeverria C, Sellers WR, Voliva CF. 2012. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 11:317–328.
35. Mansure JJ, Nassim R, Chevalier S, Rocha J, Scarlata E, Kassouf W. 2009. Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer Biol Ther 8:2339–2347.
36. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, Mazzarino MC, Fagone P, Nicoletti F, Basecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Chiarini F, Evangelisti C, Cocco L, Martelli AM. 2012a. Ras/Raf/MEK/ERK and PI3 K/PTEN/Akt/mTOR cascade inhibitors: How mutations can result in therapy resistance and how to overcome resistance. Oncotarget 3:1068–1111.
37. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, Candido S, Libra M, Basecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Cocco L, Evangelisti C, Chiarini F, Martelli AM. 2012b. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3 K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget 3:954–987.
38. Mitra AP, Datar RH, Cote RJ. 2006. Molecular pathways in invasive bladder cancer: New insights into mechanisms, progression, and target identification. J Clin Oncol 24:5552–5564.
39. Negri E, La Vecchia C. 2001. Epidemiology and prevention of bladder cancer. Eur J Cancer Prev 10:7–14.
40. Ploeg M, Aben KK, Kiemeney LA. 2009. The present and future burden of urinary bladder cancer in the world. World J Urol 27:289–293.
41. Populo H, Lopes JM, Soares P. 2012. The mTOR signalling pathway in human cancer. Int J Mol Sci 13:1886–1918.
42. Przybylo M, Litynska A, Pochec E. 2005. Different adhesion and migration properties of human HCV29 non-malignant urothelial and T24 bladder cancer cells: Role of glycosylation. Biochimie 87:133–142.
43. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang X, Shen TH, Matos T, Shen MM, Cordon-Cardo C, Abate-Shen C. 2009. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 23:675–680.
44. Pymar LS, Platt FM, Askham JM, Morrison EE, Knowles MA. 2008. Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms. Hum Mol Genet 17:2006–2017.
45. Rodon J, Brana I, Siu LL, De Jonge MJ, Homji N, Mills D, Di Tomaso E, Sarr C, Trandafir L, Massacesi C, Eskens F, Bendell JC. 2014. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3 K inhibitor, in patients with advanced solid tumors. Invest New Drugs 32:670–681.
46. Sengupta S, Peterson TR, Sabatini DM. 2010. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 40:310–322.
47. Sgnaolin V, Pereira TC, Bogo MR, Zanin R, Battastini AM, Morrone FB, Campos MM. 2013. Functional and molecular characterization of kinin B1 and B 2 receptors in human bladder cancer: Implication of the PI3Kgamma pathway. Invest New Drugs 31:812–822.
48. Shaw RJ, Cantley LC. 2006. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441:424–430.
49. Sio TT, Ko J, Gudena VK, Verma N, Chaudhary UB. 2014. Chemotherapeutic and targeted biological agents for metastatic bladder cancer: A comprehensive review. Int J Urol 21:630–637.
50. Tazzari PL, Cappellini A, Ricci F, Evangelisti C, Papa V, Grafone T, Martinelli G, Conte R, Cocco L, McCubrey JA, Martelli AM. 2007. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 21:427–438.
51. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M. 2005. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602–4608.